Why this is important – The DBT News

0


Xeris Biopharma Holdings Inc. [NASDAQ: XERS] traded high on 11/15/21 posting a gain of 15.89 after which it closed today’s session at $ 2.48. The company’s report on November 10, 2021 Xeris Biopharma to release its third quarter 2021 financial results and other highlights.

Acquisition of Strongbridge Biopharma completed on October 5, 2021; integration completed.


3 tiny actions ready to explode The world’s largest investor, Warren Buffett, has a simple formula for making big money in the markets. He buys valuable goods when they are very cheap. For stock market investors, that means buying cheap small cap stocks like these with huge upside potential.

We have implemented an early warning service to help savvy investors take full advantage of small cap stocks designed for big returns.

Click here for full details and to register for free

Sponsored


Q3 pro forma net sales of $ 22.5 million: Gvoke® and Keveyis® $ 11.0 million and $ 11.5 million, respectively.

The trading session results contributed to the change of hands of more than 6,862,616 shares. In the past week, the price volatility of Xeris Biopharma Holdings Inc. is 8.22% while the volatility in the past month is 7.34%.

XERS share market capitalization reached $ 300.60 million, with 66.50 million shares outstanding and 55.44 million shares in the current float. Compared to the average trading volume of 3.29 million shares, XERS reached a trading volume of 6,862,616 in the last trading day, which is why market watchers consider the share to be active.

What are the top market gurus saying about Xeris Biopharma Holdings Inc. [XERS]?

Based on careful, factual analysis by Wall Street experts, the current consensus on the target price for XERS shares is $ 6.31 per share. Analysis of target price and stock performance is usually carefully considered by market experts, and the current Wall Street consensus for XERS stock is a recommendation set at 1.70. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means a strong sell, 4 represents a sell, 3 is a hold, and 2 indicates a buy.

HC Wainwright made an estimate for the shares of Xeris Biopharma Holdings Inc., retaining their opinion on which stock to buy, with their previous recommendation of October 29, 2021. Although these analysts have maintained the previous recommendation, RBC Capital Mkts has increased its target price to Surpass. The new target price note was released on April 7, 2021, representing the official price target for Xeris Biopharma Holdings Inc. stock. Previously, the target price had yet another increase to $ 12, while Piper Sandler analysts maintained an overweight rating on XERS stock.

The Average True Range (ATR) for Xeris Biopharma Holdings Inc. is set at 0.16, with the price-to-sales ratio of the XERS share over the last 12 months being 8.52.

How has the XERS share performed recently?

Xeris Biopharma Holdings Inc. [XERS] gaining in the green zone at the end of last week, gaining in a positive trend and gaining 22.17. With this latest performance, XERS shares have gained 24.00% over the past four weeks, also falling -30.92% over the past 6 months, not to mention a drop of -53.03% over the past four weeks. of the last year of negotiations.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result above 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent neutral market dynamics. XERS stock’s current RSI for the last two-week period is set at 66.17, with the RSI for the last single of the trades reaching 74.71, and the three-week RSI is set at 59.66 for Xeris Biopharma Holdings Inc. [XERS]. The current moving average for the last 50 trading days for this stock is 2.22, while it was recorded at 2.11 for the last week of trading and 3.56 for the last 200 days.

Xeris Biopharma Holdings Inc. [XERS]: Deepening of the fundamentals

The operating margin of any stock indicates how profitable the investment would be, and Xeris Biopharma Holdings Inc. [XERS] The stocks currently have an operating margin of -400.52 and a gross margin of +54.84. Xeris Biopharma Holdings Inc.’s net margin is currently recorded at -446.00.

The total ROI for XERS is now -84.59, given the latest swing, and the ROI for the company is -94.19. The return on equity for this stock declined to -378.20, with a return on assets of -67.98. With regard to the capital structure of this company, Xeris Biopharma Holdings Inc. [XERS] has a ratio of total debt to total equity set at 257.76. In addition, the total debt of XERS to total capital is recorded at 72.05, with the total debt to total assets ending at 54.68. Long-term debt to equity of the company is recorded at 257.76, with long-term debt to total capital now at 72.05.

Reflecting on the efficiency of the company’s workforce, Xeris Biopharma Holdings Inc. [XERS] managed to generate an average of -506,333 $ per employee. The company’s receivables revenue is 3.27 with total asset revenue recorded at a value of 0.15. Equally interesting and compelling is the liquidity data from Xeris Biopharma Holdings Inc., with a quick ratio of 3.00 and a current ratio set at 3.30.

Analysis of the results of Xeris Biopharma Holdings Inc. [XERS]

With the latest financial reports released by the company, Xeris Biopharma Holdings Inc. posted EPS of -0.41 / share, while average EPS was forecast by analysts at -0.38 / share. When compared, the two values ​​show that the company fails the estimates with a surprise factor of -7.90%. The company’s progress can be seen through the prism of the EPS growth rate, while Wall Street analysts focus on forecasting the 5-year EPS growth rate for XERS.

>> 7 top choices for the post-pandemic economy

Insider Trading Positions for Xeris Biopharma Holdings Inc. [XERS]

There is currently approximately $ 129 million, or 25.40% of XERS shares, in the hands of institutional investors. The three main institutional holders of XERS shares are: VANGUARD GROUP INC, holding 5,176,352 shares with an approximate value of $ 12.84 million in XERS shares; and STONEPINE CAPITAL MANAGEMENT, LLC, which currently owns $ 11.13 million of XERS shares and owns nearly 35.82% of the company’s market capitalization.

The positions in the shares of Xeris Biopharma Holdings Inc. held by institutional investors increased at the end of November and at the time of the reference period of November, when 36 institutional holders increased their position in Xeris Biopharma Holdings Inc. [NASDAQ:XERS] approximately 4,333,966 shares. In addition, 74 investors reduced their positions by approximately 16,029,626 shares, while 23 investors held positions with 31,455,171 shares. The mentioned changes place institutional holdings at 51,818,763 shares, according to the latest report filed with the SEC. XERS share had 11 new institutional investments for a total of 193,023 shares, while 37 institutional investors sold positions of 10,950,132 shares during the same period.


Share.

About Author

Comments are closed.